Skip to main content

Table 3 Tumor growth inhibition and tumor growth delay of evofosfamide in NPC xenograft models

From: Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo

Group

TGI (%)

TGD500 (day)

TGD1000 (day)

Control

0

10.4

13.2

DDP

42

11.4

18.3

Evofosfamide 50 μmol/L

43

11.2

15.4

Evofosfamide 50 μmol/L + DDP

49

11.3

18.9

Evofosfamide 75 μmol/L

55

11.4

21.2

Evofosfamide 75 μmol/L + DDP

71

11.2

N/A

  1. TGD500 and TGD1000 were determined as the average increase in time for the treated tumor to reach a size of 500 or 1000 mm3 compared with the control group
  2. TGI tumor growth inhibition, TGD tumor growth delay